Endocrine manifestations and long-term outcomes of patients with mitochondrial diseases
- PMID: 40382647
- PMCID: PMC12085821
- DOI: 10.1186/s13023-025-03773-6
Endocrine manifestations and long-term outcomes of patients with mitochondrial diseases
Abstract
Background: Endocrine dysfunctions are commonly associated with mitochondrial diseases. This study aimed to investigate clinical characteristics and outcomes of endocrine manifestations in patients with mitochondrial diseases.
Methods: This study included 54 patients from 47 families with mitochondrial diseases who were genetically confirmed; 49 patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), four with Pearson syndrome, and one with Kearns-Sayre syndrome (KSS). Clinical and endocrine findings were retrospectively reviewed.
Results: The median age at diagnosis was 18.5 years (range, 0.1 - 49 years). In 49 patients with MELAS, the mean height and weight standard deviation scores were - 2.0 ± 1.3 and - 2.6 ± 1.6, respectively, with 44.9% (n = 22) of the patients exhibiting short stature at diagnosis. Twenty-three (46.9%) patients with MELAS were diagnosed with diabetes mellitus (DM) at a median age of 26 years (range, 12 - 50 years). Interestingly, papillary thyroid cancer was observed in 10.2% of patients (n = 5) with MELAS at a mean age of 34.1 ± 6.9 years. One patient with MELAS and one with KSS exhibited hypoparathyroidism. Patients with Pearson syndrome and KSS exhibited more severe short stature. Adrenal insufficiency was noted in 50% of the patients with Pearson syndrome.
Conclusions: In 20% of patients with MELAS, endocrine dysfunctions including having a short stature, DM, and hypoparathyroidism preceded the onset of neurological manifestations. Papillary thyroid cancer occurred in 10% of patients with MELAS. Patients with Pearson syndrome and KSS showed profound growth retardation and multisystem dysfunctions, such as chronic kidney disease and neurological defects, which contributed to increased mortality.
Keywords: Adrenal insufficiency; Diabetes mellitus; Hypoparathyroidism; Kearns–Sayre syndrome; Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes; Pearson syndrome.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the Institutional Review Board of the Asan Medical Center, Seoul, Korea (IRB No. 2024 − 0271). Consent for publication: All authors agreed to publish the manuscript. Competing interests: The authors declare that they have no completing interests.
Figures
Similar articles
-
Adrenal insufficiency in a child with MELAS syndrome.Brain Dev. 2014 Nov;36(10):924-7. doi: 10.1016/j.braindev.2013.12.009. Epub 2014 Feb 5. Brain Dev. 2014. PMID: 24508408
-
Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome.Ann N Y Acad Sci. 2008 Oct;1142:133-58. doi: 10.1196/annals.1444.011. Ann N Y Acad Sci. 2008. PMID: 18990125 Review.
-
Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS).Pediatr Neurol. 2016 Nov;64:59-65. doi: 10.1016/j.pediatrneurol.2016.08.016. Epub 2016 Aug 26. Pediatr Neurol. 2016. PMID: 27671241
-
Endocrine disorders in a patient with a suspicion of a mitochondrial disease, MELAS syndrome - a case report and literature review.Pediatr Endocrinol Diabetes Metab. 2021;27(3):213-218. doi: 10.5114/pedm.2021.107713. Pediatr Endocrinol Diabetes Metab. 2021. PMID: 34596368 Free PMC article. Review.
-
MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.Mol Genet Metab. 2015 Sep-Oct;116(1-2):4-12. doi: 10.1016/j.ymgme.2015.06.004. Epub 2015 Jun 15. Mol Genet Metab. 2015. PMID: 26095523 Review.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical